Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 1;20(1):747.
doi: 10.1186/s12884-020-03432-7.

Supportive medication in cancer during pregnancy

Flora Zagouri  1 , Nikolaos Dedes  2 , Alkistis Papatheodoridi  2 , Michael Liontos  2 , Meletios Athanasios Dimopoulos  2
Affiliations
Review

Supportive medication in cancer during pregnancy

Flora Zagouri et al. BMC Pregnancy Childbirth. .

Abstract

While pregnancy-related malignancies are quite rare, their incidence is increasing and thus affecting more and more women nowadays. Their management, however, with both chemotherapy and supportive agents remains quite challenging and it seems crucial to define the optimal treatment for this special population. Concerning supportive medication, it is clinically significant to determine whether commonly used agents, including Granulocyte Colony-Stimulating Factors, Erythropoiesis-stimulating agents, Bisphosphonates, Anticoagulation agents, Antiemetics and Glucocorticoids are indeed effective in ameliorating chemotherapy side effects. Meanwhile, it is of great importance that the administration of any of these agents is safe for both mother and fetus. This review aims to provide a précis of the current literature regarding both safety and efficacy of all categories of supportive medication during pregnancy.

Keywords: Aanticoagulation agents; Antiemetics; Erythropoiesis-stimulating agents; Ggranulocyte colony-stimulating factors; Glucocorticoids; Ooncology patients; Pregnancy supportive care; bisphosphonates.

PubMed Disclaimer

Conflict of interest statement

Dr Zagouri has received honoraria from participation in advisory boards from Astra-Zeneca, Pfizer, Novartis, Roche and Merck.

Prof Dimopoulos M.A. has received honoraria from participation in advisory boards from Celgene, Takeda, Amgen, Janssen, Bristol-Myers-Squibb.

References

    1. Zagouri F, Psaltopoulou T, Dimitrakakis C, Bartsch R, Dimopoulos MA. Challenges in managing breast cancer during pregnancy. J Thorac Dis. 2013;5(SUPPL.1):1–6. - PMC - PubMed
    1. Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019. - PubMed
    1. Eastwood-Wilshere N, Turner J, Oliveira N, Morton A. Cancer in Pregnancy. Asia Pac J Clin Oncol. 2019;(January):1–13. - PubMed
    1. Hepner A, Negrini D, Hase EA, Exman P, Testa L, Trinconi AF, et al. Cancer During Pregnancy: The Oncologist Overview. World J Oncol. 2019;10(1):28–34. doi: 10.14740/wjon1177. - DOI - PMC - PubMed
    1. Avivi I, Farbstein D, Brenner B, Horowitz NA. Non-Hodgkin lymphomas in pregnancy: Tackling therapeutic quandaries. Blood Rev [Internet]. 2014;28(5):213–20. Available from: 10.1016/j.blre.2014.06.004. - PubMed

MeSH terms